Subramanian, Ayshwarya http://orcid.org/0000-0002-4134-7612
Sidhom, Eriene-Heidi http://orcid.org/0000-0002-2658-9672
Emani, Maheswarareddy
Vernon, Katherine
Sahakian, Nareh
Zhou, Yiming
Kost-Alimova, Maria
Slyper, Michal
Waldman, Julia
Dionne, Danielle http://orcid.org/0000-0002-8338-4323
Nguyen, Lan T.
Weins, Astrid
Marshall, Jamie L. http://orcid.org/0000-0002-2364-391X
Rosenblatt-Rosen, Orit
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Greka, Anna http://orcid.org/0000-0001-5697-7791
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK099465, DK095045)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
the Slim Initiative for Genomic Medicine in the Americas (SIGMA), and an NDSEG fellowship
Article History
Received: 4 October 2019
Accepted: 5 November 2019
First Online: 29 November 2019
Competing interests
: A.G. has a financial interest in Goldfinch Biopharma, which was reviewed and is managed by Brigham and Women’s Hospital and Partners HealthCare and the Broad Institute of MIT and Harvard in accordance with their conflict of interest policies. A.R. is a founder and equity holder of Celsius Therapeutics and an SAB member of ThermoFisher Scientific, Neogene Therapeutics and Asimov. The remaining authors declare no competing interests.